



Nutrición Hospitalaria



Trabajo Original

Otros

Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico *Los pacientes graves con COVID-19 tienen deficiencia grave de vitamina D en el noreste de México*

Edgar P. Rodríguez-Vidales¹, Denise Garza-Carrillo¹, Ana M. Salinas-Martínez^{2,3}, Olivia A. Robles-Rodríguez¹, Roberto Montes de Oca-Luna¹, Consuelo Treviño-Garza⁴, Alma R. Marroquín-Escamilla¹, Manuel E. de la O-Cavazos⁴

¹Secretaría de Salud de Nuevo León. ²Unidad de Investigación en Epidemiología y Servicios de Salud. Instituto Mexicano del Seguro Social. ³Facultad de Salud Pública y Nutrición. Universidad Autónoma de Nuevo León. ⁴Departamento de Pediatría. Hospital Universitario Dr. José Eleuterio González. Universidad Autónoma de Nuevo León. Monterrey, Nuevo León. México

Abstract

Objective: the association between vitamin D and COVID-19 severity is not consistent. We compared prevalences and analyzed the association between vitamin D deficiency and COVID-19 severity in Northeast Mexico.

Methods: this was a cross-sectional study with individuals consecutively included at a referral diagnostic center during March-September 2020 (n = 181). Concurrently, every patient admitted to intensive care was also consecutively included (n = 116). Serum 25(OH)D < 20 ng/mL was considered vitamin D deficiency. Descriptive, ANOVA, and multivariate ordinal regression analyses were performed.

Results: vitamin D deficiency prevalence was 63.8 % (95 % CI, 54.7, 72.0) in severe COVID-19; 25.6 % (95 % CI, 17.4, 36.0) in mild COVID-19; and 42.4 % (95 % CI, 33.2, 52.3) in non-diseased individuals. Vitamin D deficiency increased 5 times the odds of severe COVID-19 (95 % CI, 1.1, 24.3), independently of sex, age, body mass index, and inflammatory markers.

Conclusions: this study is the first report of vitamin D deficiency in Northeast Mexico. Vitamin D deficiency was associated with COVID-19 severity.

Keywords:

Vitamin D deficiency. SARS-CoV-2. Laboratory parameters. COVID-19. Serum 25(OH)D.

Resumen

Objetivo: la asociación entre la vitamina D y la gravedad de la COVID-19 no es consistente. Se comparó la prevalencia y se analizó la asociación de la deficiencia de vitamina D con la gravedad de los pacientes con COVID-19 en el noreste de México.

Métodos: este fue un estudio transversal. Se incluyó consecutivamente a individuos de un centro de diagnóstico de referencia durante marzo-septiembre de 2020 (n = 181). Paralelamente, se reclutó a todos los pacientes que ingresaron a cuidados intensivos en ese mismo periodo (n = 116). Se consideró que había deficiencia de vitamina D ante cifras de 25(OH)D sérica < 20 ng/ml. Se realizaron un análisis descriptivo, un ANOVA y una regresión ordinal multivariante.

Resultados: la prevalencia de la deficiencia de vitamina D fue del 63,8 % (IC del 95 %: 54,7; 72,0) en la COVID-19 grave, del 25,6 % (IC del 95 %: 17,4; 36,0) en la COVID-19 leve y del 42,4 % (IC del 95 %: 33,2; 52,3) sin COVID-19. La deficiencia aumentó 5 veces las probabilidades de una COVID-19 grave (IC del 95 %: 1,1; 23,9) independientemente del sexo, la edad, el índice de masa corporal y los marcadores inflamatorios.

Conclusiones: este estudio es el primer informe de la deficiencia de vitamina D en el noreste de México. La deficiencia de vitamina D se asoció con la gravedad de la COVID-19.

Palabras clave:

Deficiencia de vitamina D. SARS-CoV-2. Parámetros de laboratorio. COVID-19. 25(OH)D sérica.

Received: 23/08/2021 • Accepted: 18/01/2022

Conflicts of interests: the authors declare no conflicts of interest.

Author contributions: conceptualization, methodology and formal analysis: ERV, RMDOL, and DGC; writing—original draft preparation, data curation, formal analysis: ORR and ASM; design, analysis, writing—review and editing: MDOC, CTG and AME. All authors have read and agreed to the published version of the manuscript.

Rodríguez-Vidales EP, Garza-Carrillo D, Salinas-Martínez AM, Robles-Rodríguez OA, Montes de Oca-Luna R, Treviño-Garza C, Marroquín-Escamilla AR, de la O-Cavazos ME. Severe COVID-19 patients have severe vitamin D deficiency in Northeast Mexico. *Nutr Hosp* 2022;39(2):393-397

DOI: <http://dx.doi.org/10.20960/nh.03731>

Correspondence:

Manuel E. De la O-Cavazos; Alma R. Marroquín-Escamilla. Torre Administrativa, Piso 8. Calle Washington, 2000. Col. Obrera. 64000 Monterrey, Nuevo León. México
e-mail: publicacion.investssnl@gmail.com;
alma.marroquin@saludnl.gob.mx

INTRODUCTION

COVID-19 was originated in Wuhan, China, at the beginning of December 2019. Since then a rapid spread has beaten the entire world (1). Mexico has been one of the most affected countries ranking twelfth in number of new cases and fourth in mortality as of January 20th, 2021 (2). High infectivity and considerable variability had defined the clinical presentation of the disease. More than 40 % of patients are symptomless, 30 % to 45 % manifest mild symptoms, and 15 % manifest severe symptoms with hospitalization or intensive care (3). COVID-19 severity has been linked to elevated oxidative stress, exaggerated immune response, uncontrollable liberation of proinflammatory cytokines, and activation of coagulating factors, all of which contribute to severe inflammation (4,5). The effect of vitamin D on maintaining bone health and calcium-phosphorus metabolism is well known. But also, it possesses anti-inflammatory antifibrotic and antioxidant qualities. It modulates the immune system (6,7) and its anti-inflammatory function explains the beneficial effect on immune responses and antimicrobial agent production (8). Also, vitamin D regulates the renin-angiotensin system and expression of angiotensin-converting enzyme 2 linked to a lung protective effect (9,10).

Scientists have centralized their attention on factors that can control or prevent COVID-19 severity. Vitamin D has been suggested for such intentions (11), but its role on SARS-CoV-2 severity is still under investigation (12,13). D'Avolio et al. described lower vitamin D levels in patients with COVID-19 symptomatology for the first time (14). There are observational studies that have determined an association between vitamin D levels and COVID-19 severity, but their findings are not consistent (11,15-16); and the literature is limited in Hispanic American populations (17). The objective of the present study was to compare vitamin D concentrations and prevalence of vitamin D deficiency between individuals with no COVID-19 and patients with mild and severe COVID-19. Also, to analyze the association between vitamin D deficiency and COVID-19 severity in Northeast Mexico.

MATERIALS AND METHODS

This was a cross-sectional study. A non-random sampling was carried out in two sites, a referral diagnostic primary care center and an intensive care unit from a secondary care hospital. All individuals with suspected symptoms of COVID-19 who attended the referral center for a real-time polymerase chain reaction (PCR) test between March and September 2020 were consecutively included ($n = 181$). Concurrently, every patient admitted to intensive care with a diagnosis of COVID-19 was also consecutively included ($n = 116$). Inclusion criteria consisted of age ≥ 18 years and no pregnancy. The sample size in each group was sufficient for a power greater than 80 % and alpha greater than 95 % given the 10 % observed outcome in the unexposed group and the unadjusted odds ratio obtained. The protocol was approved by the "Dr. Bernardo Sepulveda" Hospital's Committee of Ethics and Health Research (HMBSSNL-2020/878). An informed consent was provided by all the participants.

COVID-19 SEVERITY STATUS

COVID-19 severity status was classified as negative (individuals with suspected symptoms of COVID-19 with a negative PCR test at the referral diagnostic primary care center), mild (individuals with suspected symptoms of COVID-19 with a positive PCR test at the referral diagnostic primary care center and who were maintained on ambulatory care), and severe (patients admitted to intensive care with a COVID-19 diagnosis).

VITAMIN D STATUS

Serum 25(OH)D was estimated using the 25-OH Vitamin D kit (ARCHITECT i; Abbott Laboratories; reference 5P02-25) and the Vitamin D controls (ARCHITECT; Abbott Laboratories; reference 5P02-10) on Architect i2000 SR analyzer 5P02 (Abbott Diagnostics, Chicago, USA). Values > 40 ng/mL were considered above normal, values between 30 and 39 ng/mL normal, values between 20 and 29 ng/mL mild vitamin D deficiency, values between 10 and 19 ng/mL moderate vitamin D deficiency, and values < 10 ng/mL severe vitamin D deficiency. In addition, a cut-off value of 25(OH)D < 20 ng/mL was used for combining moderate and severe vitamin D deficiency.

OTHER BIOCHEMICAL MEASUREMENTS AND DEMOGRAPHIC DATA

Lactate dehydrogenase (LDH) (U/L), C-reactive protein (mg/L), D-dimer (ng/ml), and fibrinogen (mg/L) were obtained. Also, leukocytes ($\times 10^9/L$), lymphocytes ($\times 10^9/L$), neutrophils ($\times 10^9/L$), platelets ($\times 10^9/L$), and prothrombin time (seconds). Blood samples were taken at admission to intensive care (severe COVID-19 patients) or alongside with the PCR test at the referral diagnostic primary care center (mild and no COVID-19 individuals). All laboratory measurements were prospectively collected from the clinical chart, as well as sex, age, and body mass index (BMI).

STATISTICAL ANALYSIS

Frequencies were obtained for the categorical variables, as were means and standard deviations for the non-categorical variables with normal distribution; otherwise, medians and interquartile ranges (percentile 25th and 75th) were calculated. Vitamin D deficiency point prevalence and 95 % confidence intervals (CI) were estimated for each COVID-19 severity group. The chi-square and non-parametric one-way ANOVA tests with post-hoc analysis were used to make comparisons between groups. Non-parametric coefficient correlations were also estimated between vitamin D concentration and inflammatory biomarkers. The association between vitamin D and COVID-19 severity was analyzed with a multivariate logistic ordinal regression using COVID-19 status as the dependent variable (no, mild and severe),

vitamin D as the independent variable (normal/above normal, mild, moderate, and severe deficiency), and sex, age, BMI, LDH, C-reactive protein, D-dimer, and fibrinogen as control variables.

RESULTS

The study population's mean age was 46.0 ± 17.4 years and 51.1 % were male. Male sex, mean age, mean BMI, and median blood measurements were higher in severe COVID-19 patients than in individuals with no COVID-19 ($p \leq 0.05$). All blood test results were less favorable in the severe COVID-19 group when compared to the non-COVID-19 group. As well as most of the blood tests in the mild group when compared to the non-COVID-19 group (Table I).

VITAMIN D AND COVID-19 SEVERITY STATUS

Median vitamin D was lower in the severe COVID-19 group (16.3 ng/mL; IQR, 10.2, 23.2) than in the mild (23.4 ng/mL; IQR, 19.9, 29.0) or no COVID-19 group (21.0 ng/mL; IQR, 17.6, 27.9) ($p < 0.0001$) (Fig. 1). There were no vitamin D differences by sex, but it was negatively correlated with age ($\rho = -0.13$, $p < 0.02$). Vitamin D was also negatively correlated with LDH ($\rho = -0.20$, $p < 0.0001$) and D-dimer ($\rho = -0.27$, $p < 0.0001$).

The prevalence of vitamin D < 20 ng/mL was 63.8 % (95 % CI, 54.7, 72.0) in the severe COVID-19 group, 25.6 % (95 % CI, 17.4, 36.0) in the mild COVID-19 group, and 42.4 % (95 % CI, 33.2, 52.3) in the non-COVID-19 group. Severe vitamin D deficiency increased the odds of severe COVID-19 by five times regardless of sociodemographic, BMI, and inflammatory blood markers (Table II).




Figure 1.

Vitamin D concentrations by COVID-19 severity status.

Table I. Characteristics of the study population by COVID-19 severity status

	COVID-19 severity status			Non-parametric ANOVA test		
	No disease (n = 99) (1)	Mild disease (n = 82) (2)	Severe disease (n = 116) (3)	3 vs 1	3 vs 2	2 vs 1
Age (mean \pm SD)	36.6 \pm 13.0	37.7 \pm 13.8	58.7 \pm 14.6	‡	‡	n.s.
Sex, male	41.4 %	56.1 %	56.9 %	*	n.s.	*
Body mass index	27.4 \pm 5.2	27.3 \pm 4.2	28.2 \pm 5.3	*	n.s.	n.s.
Neutrophil to lymphocyte ratio ≥ 3	20.4 %	28.0 %	93.0 %	‡	n.s.	n.s.
Median (interquartile range)						
Lactate dehydrogenase (U/L)	177 (152.5, 206.5)	205 (174, 244.5)	↑ 457 (381, 654)	‡	‡	†
C-reactive protein (mg/L)	3.1 (1.5, 10.9)	8.5 (2.8, 36.4)	↑ 115.6 (47.3, 209.6)	‡	‡	‡
D-dimer (ng/mL)	249 (157.5, 401.5)	404 (219, 562)	↑ 1,931 (742, 4,741)	‡	‡	*
Fibrinogen (mg/dL)	↑ 478.5 (402.5, 562)	↑ 517.5 (448, 660.5)	↑ 822 (632, 973)	‡	‡	‡
Leukocytes $\times 10^9/L$	7.6 (6.4, 9)	6.1 (4.8, 7.4)	↑ 12.2 (9.2, 15.9)	‡	‡	†
Platelets $\times 10^9/L$	262 (227, 297.5)	229.5 (181, 264)	249 (184.5, 307.5)	*	n.s.	†
Prothrombin time (seconds)	11 (10.5, 11.6)	11.1 (10.5, 11.8)	13 (11.9, 14.3)	‡	‡	n.s.

* $p \leq 0.05$, † $p < 0.01$, ‡ $p < 0.001$; n.s. = non-significance, $p > 0.05$.

Table II. Vitamin D multivariate logistic ordinal regression on COVID-19 severity status

	COVID-19 severity status			Odds ratios (95 % confidence interval)		
	No disease (n = 99)	Mild disease (n = 82)	Severe disease (n = 116)	Unadjusted	Adjusted ^a	Adjusted ^b
Vitamin D category						
Normal/Above (≥ 30 ng/mL)	16.2 %	24.4 %	10.3 %	1.0	1.0	1.0
Mild deficiency (20-29 ng/mL)	41.4 %	50.0 %	25.9 %	1.0 (0.5, 1.8)	0.93 (0.48, 1.79)	0.76 (0.35, 1.7)
Moderate deficiency (10-19 ng/mL)	38.4 %	24.4 %	40.5 %	1.5 (0.8, 2.7)	1.51 (0.77, 2.98)	0.85 (0.38, 1.9)
Severe deficiency (< 10 ng/mL)	4.0 %	1.2 %	23.3 % [†]	10.8 (3.6, 31.9) [†]	9.83 (3.0, 32.1) [†]	5.08 (1.07, 24.3) [*]
Lactate dehydrogenase (> 333 U/L)	2.0 %	11.1 %	82.5 % [†]	--	--	22.0 (8.3, 58.5) [†]
D-dimer (≥ 500 ng/mL)	16.7 %	35.8 %	86.0 % [†]	--	--	3.4 (1.7, 6.8) [†]

^aFor sex, age, and body mass index. ^bOther variables in the model were sex, age, body mass index, C-reactive protein, and fibrinogen. * $p < 0.05$; [†] $p < 0.0001$.

DISCUSSION

The objective of the present study was to compare vitamin D concentrations and prevalence of severe vitamin D deficiency between individuals with no COVID-19 and patients with mild and severe COVID-19. There was a difference in prevalence of vitamin D deficiency between groups (< 20 ng/mL), although it was not in ascending order from non-COVID-19 to moderate and severe COVID-19. De Smet et al. (18) reported vitamin D deficiency rates increasing from 55 % in stage 1 (pulmonary ground-glass opacities) to 67 % in stage 2 and 74 % in stage 3 (diffuse alveolar damage and fibrosis). AlSafar et al. (19) did not find any differences by COVID-19 severity. They identified 76 % of vitamin D deficiency in asymptomatic, 65 % in mild, 67 % in moderate, and 61 % in severe COVID-19 patients ($p > 0.05$). Comparison of vitamin D deficiency in COVID-19 patients in intensive care between countries shows 61 % in the United Arab Emirates (19), 72.1 % in Italy (20), 74 % in Belgium (18), 96.8 % in India (11), and 63.8 % in Northeast Mexico (this study). The prevalence in healthy populations varies. It has been estimated at 37.3 % in European countries (21) and at 40 % (summer time) and 65 % (winter time) in Northeast Mexico (22). Vitamin D deficiency was not associated with sex but with age — the older the age, the lower the vitamin D concentration, contrary to De Smet et al. (18), who identified that male sex doubled the odds of vitamin D < 20 ng/mL but no association could be found with age. Adami et al. (20) found no association with age or sex. Major causes of vitamin D deficiency are inadequate exposure to sunlight, obesity, and kidney disease, among others (23,24). Variations in the causes of deficiency are probably also the origin of differences in prevalence values in addition to severity status.

We identified that the relationship between vitamin D, D-dimer, and LDH was inverse, indicating that the intensity of the inflammatory response was high with low levels of vitamin D. Hernandez et al. (17) also identified an inverse correlation with D-dimer levels.

Adami et al. (20) did not find such association but did find one with C-reactive protein. LDH is an important marker of lung damage and D-dimer reflects the progression of disease toward an unfavorable clinical outcome (25). In this study, LDH, D-dimer, C-reactive protein, fibrinogen, and leukocyte values were significantly higher in severe COVID-19. Besides, D-dimer increased 3 times and LDH increased more than twenty times the odds of severe COVID-19. Vitamin D itself is linked to anti-inflammatory antifibrotic qualities, so if vitamin D is low, anti-inflammatory antifibrotic properties fail, and prevention or reduction of COVID-19 severity also fails.

Median vitamin D concentrations were lower in severe COVID-19 than in mild COVID-19 patients with a difference of -7.4 ng/dL (95 % CI, -10.5, -4.3), which was consistent with a review study showing a weighted mean difference of -7.2 ng/mL (95 % CI, -10.9, -4.3) between severe and less severe COVID-19 patients (26). De Smet et al. (18) also reported lower median vitamin D in most severe versus less severe COVID-19 patients. Vitamin D deficiency (< 12 ng/mL) increased 5 times the odds of severe COVID-19 regardless of sex, age, BMI, LDH, D-dimer, C-reactive protein, and fibrinogen. Ye et al. (15) reported an odds ratio of 15.2 (95 % CI, 1.2-187.5) regardless of age, sex, renal failure, diabetes, and hypertension in China. Also, Jain et al. (11) found an association between vitamin D deficiency (< 20 ng/dL) and intensive care admission due to severe COVID disease in India. However, the literature is not consistent. Studies by Cereda et al. (27), Hernández et al. (17), and Szeto et al. (28) have not found an association. AlSafar et al. (19) did not identify that vitamin D < 20 ng/mL increased the odds of severe COVID-19, but they did with vitamin D < 12 ng/mL, independently of sex, age, and comorbidities. The review study by Kazemi et al. (26) estimated an overall effect size of 2.6 (95 % CI: 1.7, 4.0) on a composite measure of COVID-19 severity (at least 1 of the following outcomes: acute respiratory distress syndrome, mechanical ventilation, ICU admission, length of hospitalization, and death). But no significant association was found when intensive care was the only measure of severity (16,17,29).

LIMITATIONS

No data was available on prior vitamin D supplementation. So, prevalence estimation on vitamin D deficiency might not be accurate. However, the association result is not expected to be affected, since such an association occurred between current vitamin level and current disease severity, regardless of how that level was reached. Given the cross-sectional study design, there is no certainty in directionality — if vitamin D deficiency influenced disease severity, or if deficiency was a consequence of disease severity. A cohort design is needed for distinguishing directionality. Better yet, clinical trials on vitamin D supplementation are on their way. Chronic conditions such as hypertension, diabetes, cancer, or cardiovascular diseases may contribute to poor COVID-19 prognosis; we did not have this information available, but we had inflammation biomarkers instead. Finally, only non-pregnant adults were recruited from one referral diagnostic primary care center and one intensive care unit. So, caution is needed when generalizing results to children and pregnant women. Further research is needed with multicenter participation considering populations younger than 18 years and pregnant women.

CONCLUSIONS

This study is the first report of vitamin D deficiency in no-, mild, and severe COVID-19 subjects in Northeast Mexico. Lower vitamin D concentrations and a higher prevalence of vitamin D deficiency were present in patients with severe COVID-19. We found an inverse relationship between vitamin D, LDH, and D-dimer, and an association between vitamin D deficiency and COVID-19 severity. Yet, large-scale observational studies and randomized controlled trials of vitamin D supplementation for controlling COVID-19 severity are necessary in Hispanic American populations.

REFERENCES

- Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. *Global Health Research and Policy* 2020;5(1):6. DOI: 10.1186/s41256-020-00135-6
- WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet] [cited 2021 Feb 18]. Available from: <https://covid19.who.int/>
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323(13):1239. DOI: 10.1001/jama.2020.2648
- Butt Y, Kurdowska A, Allen TC. Acute Lung Injury: A Clinical and Molecular Review. *Arch Pathol Lab Med* 2016;140(4):345-50. DOI: 10.5858/arpa.2015-0519-RA
- Hughes KT, Beasley MB. Pulmonary Manifestations of Acute Lung Injury: More Than Just Diffuse Alveolar Damage. *Arch Pathol Lab Med* 2017;141(7):916-22. DOI: 10.5858/arpa.2016-0342-RA
- White JH. Vitamin D metabolism and signaling in the immune system. *Rev Endocr Metab Disord* 2012;13(1):21-9. DOI: 10.1007/s11154-011-9195-z
- McCartney DM, O'Shea PM, Faul JL, Healy MJ, Byrne G, Griffin TP, et al. Vitamin D and SARS-CoV-2 infection—evolution of evidence supporting clinical practice and policy development. *Ir J Med Sci* 2020;1-13. DOI: 10.1007/s11845-020-02427-9
- Gois PHF, Ferreira D, Olenski S, Seguro AC. Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? *Nutrients* 2017;9(7):E651. DOI: 10.3390/nu9070651
- Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. *Crit Care Med* 2011;39(4):671-7. DOI: 10.1097/CCM.0b013e318206ccdf
- de Haan K, Groeneveld AJ, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. *Crit Care* 2014;18(6):660. DOI: 10.1186/s13054-014-0660-4
- Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. *Scientific Reports* 2020;10(1):20191. DOI: 10.1038/s41598-020-77093-z
- Ohaegbulam KC, Swalih M, Patel P, Smith MA, Perrin R. Vitamin D Supplementation in COVID-19 Patients: A Clinical Case Series. *Am J Ther* 2020;e485-90. DOI: 10.1097/MJT.0000000000001222
- Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res* 2020;1-4. DOI: 10.21203/rs.3.rs-21211/v1
- D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, et al. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. *Nutrients* 2020;12(5). DOI: 10.3390/nu12051359
- Ye K, Tang F, Liao X, Shaw BA, Deng M, Huang G, et al. Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?—A Case-Control Study. *J Am Coll Nutr* 2020;1-8. DOI: 10.1080/07315724.2020.1826005
- Panagiotou G, Tee SA, Ihsan Y, Athar W, Marchitelli G, Kelly D, et al. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. *Clin Endocrinol (Oxf)* 2020;10.1111/cen.14276. DOI: 10.1101/2020.06.21.20136903
- Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández-Hernández MA, López-Hoyos M, et al. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection. *J Clin Endocrinol Metab* 2021;106(3):e1343-53. DOI: 10.1210/clinem/dgaa733
- De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Serum 25(OH) D Level on Hospital Admission Associated With COVID-19 Stage and Mortality. *Am J Clin Pathol* 2021;155(3):381-8. DOI: 10.1093/ajcp/aqaa252
- AlSafar H, Grant WB, Hijazi R, Uddin M, Alkaabi N, Tay G, et al. COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents. *Nutrients* 2021;13(5):1714. DOI: 10.3390/nu13051714
- Adami G, Giollo A, Fassio A, Benini C, Bertoldo E, Bertoldo F, et al. Vitamin D and disease severity in coronavirus disease 19 (COVID-19). *Reumatismo* 2020;72(4):189-96. DOI: 10.4081/reumatismo.2020.1333
- Cashman KD, Dowling KG, Škrabáková Z, Gonzalez-Gross M, Valtuena J, De Henauw S, et al. Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr* 2016;103(4):1033-44. DOI: 10.3945/ajcn.115.120873
- Elizondo-Montemayor L, Castillo EC, Rodríguez-López C, Villarreal-Calderón JR, Gómez-Carmona M, Tenorio-Martínez S, et al. Seasonal Variation in Vitamin D in Association with Age, Inflammatory Cytokines, Anthropometric Parameters, and Lifestyle Factors in Older Adults. *Mediators Inflamm* 2017;2017:5719461. DOI: 10.1155/2017/5719461
- Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. *Proc Natl Acad Sci U S A* 2008;105(2):668-73. DOI: 10.1073/pnas.0710615105
- Dusso AS. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. *Kidney Int Suppl* 2011;1(4):136-41. DOI: 10.1038/kisup.2011.30
- Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta* 2020;510:475-82. DOI: 10.1016/j.cca.2020.08.019
- Kazemi A, Mohammadi V, Aghababae SK, Golzarand M, Clark CCT, Babajafari S. Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis. *Advances in Nutrition [Internet]* 2021 [cited 2021 Jul 19]. Available from: <https://www.scienceopen.com/document?vid=0ab4f2e7-d029-4eae-9f63-5fb0192f18e9>
- Cereda E, Bogliolo L, Klersy C, Lobascio F, Masi S, Crotti S, et al. Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital. *Clin Nutr* 2021;40(4):2469-72. DOI: 10.1016/j.clnu.2020.10.055
- Szeto B, Zucker JE, LaSota ED, Rubin MR, Walker MD, Yin MT, et al. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients. *Endocr Res* 2021;46(2):66-73. DOI: 10.1080/07435800.2020.1867162
- Maghbooli Z, Sahraian MA, Ebrahimi M, Pazoki M, Kafan S, Tabriz HM, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. *PLoS One* 2020;15(9):e0239799. DOI: 10.1371/journal.pone.0239799